蛋白酶体抑制剂治疗脑胶质瘤的研究进展  

Research Progress on Proteasome Inhibitors for the Treatment of Glioma

作　　者：孔繁栋 韩光魁[2] 沈嵩民 

机构地区：[1]济宁医学院临床医学院,山东 济宁 [2]济宁医学院附属医院神经外科,山东 济宁

出　　处：《临床个性化医学》2025年第1期244-251,共8页Journal of Clinical Personalized Medicine

摘　　要：脑胶质瘤是成人中枢神经系统中最常见的恶性肿瘤之一,尤其是恶性程度高的胶质母细胞瘤,其预后极差,传统的手术、放疗和化疗等治疗方式效果有限。蛋白酶体抑制剂作为一种新兴的抗肿瘤治疗方式,通过抑制细胞蛋白降解的通路,干扰细胞内蛋白质稳态,进而诱导肿瘤细胞死亡。本文综述了蛋白酶体抑制剂在脑胶质瘤治疗中的作用机制、临床前和临床研究进展,并探讨了其应用前景和面临的挑战。Gliomas are one of the most common malignant tumors in the adult central nervous system, especially highly malignant glioblastomas, which have a very poor prognosis. Traditional treatments such as surgery, radiotherapy, and chemotherapy have limited effectiveness. Proteasome inhibitors, as an emerging anti-tumor therapy, interfere with intracellular protein homeostasis by inhibiting the pathway of cellular protein degradation, thereby inducing tumor cell death. This article reviews the mechanism of action, preclinical and clinical research progress of proteasome inhibitors in the treatment of glioblastoma, and explores their application prospects and challenges.

关 键 词：蛋白酶体抑制剂 泛素–蛋白酶体系统 脑胶质瘤 硼替佐米(PS-341 Velcade) 马里佐米(NPI-0052) 

分 类 号：R73[医药卫生—肿瘤]